Kinetics of Anti–Hepatitis B Surface Antigen Titers After Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease
Authors:
- Javier P. GisbertJGJavier P. Gisbert
- Jose Ramón VillagrasaJVJose Ramón Villagrasa
- Amelia Rodríguez-NogueirasARAmelia Rodríguez-Nogueiras
- María ChaparroMCMaría Chaparro
- 1 March 2013
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (3) , 554-558
Abstract
Clinically significant hepatitis B (HB) virus infection has been documented among immunocompromised patients who do not maintain anti-hepatitis surface antigen (anti-HBs) concentrations ≥ 10 IU/L after an adequate response to the vaccine. The aims of the study were to understand the kinetics of anti-HBs titers over time in patients with inflammatory bowel disease (IBD) who initially responded to vaccination and to identify factors predictive of losing protective anti-HBs titers. Patients with IBD with a response (anti-HBs > 10 IU/L at 1-3 months) to HB virus vaccination were prospectively included. Anti-HBs titers were measured at 6 and 12 months. Anti-HBs titers were considered negative if they were 10 IU/L (191 versus 515 IU/L; P < 0.001). Treatment with anti-TNFs was the only factor associated with a higher risk of loss of anti-HBs (hazard ratio = 3.1; 95% confidence interval = 1.1-8.8; P = 0.03). A high proportion of patients with IBD with protective anti-HBs titers after vaccination lose them over time (18% per patient-year of follow-up). The risk of losing protective anti-HBs titers is 3-fold higher among patients on anti- tumor necrosis factors therapy.Keywords
This publication has 21 references indexed in Scilit:
- Efficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2012
- Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2012
- Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2011
- Vaccinations in patients with immune-mediated inflammatory diseasesRheumatology, 2010
- Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapyGut, 2010
- A Practical Guide to Vaccinating the Inflammatory Bowel Disease PatientAmerican Journal of Gastroenterology, 2010
- Viral hepatitis and inflammatory bowel diseaseInflammatory Bowel Diseases, 2010
- European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJournal of Crohn's and Colitis, 2009
- Chronic hepatitis BHepatology, 2007
- Hepatitis B Vaccine in Patients Receiving HemodialysisNew England Journal of Medicine, 1984